MX2023004538A - Compounds and methods for the treatment of ocular disorders. - Google Patents
Compounds and methods for the treatment of ocular disorders.Info
- Publication number
- MX2023004538A MX2023004538A MX2023004538A MX2023004538A MX2023004538A MX 2023004538 A MX2023004538 A MX 2023004538A MX 2023004538 A MX2023004538 A MX 2023004538A MX 2023004538 A MX2023004538 A MX 2023004538A MX 2023004538 A MX2023004538 A MX 2023004538A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- treatment
- inflammatory
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000022873 Ocular disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001530 keratinolytic effect Effects 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 229940124091 Keratolytic Drugs 0.000 abstract 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 208000010217 blepharitis Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000000744 eyelid Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063094808P | 2020-10-21 | 2020-10-21 | |
| PCT/IB2021/000708 WO2022084739A1 (en) | 2020-10-21 | 2021-10-20 | Compounds and methods for the treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004538A true MX2023004538A (en) | 2023-06-19 |
Family
ID=81290138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004538A MX2023004538A (en) | 2020-10-21 | 2021-10-20 | Compounds and methods for the treatment of ocular disorders. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230399317A1 (en) |
| EP (1) | EP4232034A1 (en) |
| JP (1) | JP2023546452A (en) |
| KR (1) | KR20230110516A (en) |
| CN (1) | CN116635032A (en) |
| AU (1) | AU2021365530A1 (en) |
| CA (1) | CA3196146A1 (en) |
| IL (1) | IL302174A (en) |
| MX (1) | MX2023004538A (en) |
| WO (1) | WO2022084739A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2830024T3 (en) * | 2007-10-19 | 2021-06-02 | Novartis Ag | Compositions and methods for the treatment of macular edema |
| US20180333357A1 (en) * | 2017-05-19 | 2018-11-22 | Ocugen, Inc. | Nanoemulsions with anti-inflammatory activity |
| US11001574B2 (en) * | 2017-11-17 | 2021-05-11 | Medichem S.A. | Process to obtain a tetrahydroisoquinoline derivative |
| KR20220003555A (en) * | 2019-04-18 | 2022-01-10 | 아주라 오프탈믹스 엘티디 | Compounds and methods for the treatment of ocular disorders |
-
2021
- 2021-10-20 IL IL302174A patent/IL302174A/en unknown
- 2021-10-20 US US18/033,055 patent/US20230399317A1/en active Pending
- 2021-10-20 CA CA3196146A patent/CA3196146A1/en active Pending
- 2021-10-20 CN CN202180086872.2A patent/CN116635032A/en active Pending
- 2021-10-20 JP JP2023524274A patent/JP2023546452A/en active Pending
- 2021-10-20 KR KR1020237016473A patent/KR20230110516A/en unknown
- 2021-10-20 MX MX2023004538A patent/MX2023004538A/en unknown
- 2021-10-20 EP EP21882227.8A patent/EP4232034A1/en active Pending
- 2021-10-20 AU AU2021365530A patent/AU2021365530A1/en active Pending
- 2021-10-20 WO PCT/IB2021/000708 patent/WO2022084739A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN116635032A (en) | 2023-08-22 |
| WO2022084739A1 (en) | 2022-04-28 |
| AU2021365530A9 (en) | 2024-02-08 |
| AU2021365530A1 (en) | 2023-06-15 |
| US20230399317A1 (en) | 2023-12-14 |
| CA3196146A1 (en) | 2022-04-28 |
| JP2023546452A (en) | 2023-11-02 |
| EP4232034A1 (en) | 2023-08-30 |
| KR20230110516A (en) | 2023-07-24 |
| IL302174A (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020212760A3 (en) | Compounds and methods for the treatment of ocular disorders | |
| MX2023004537A (en) | Compounds and methods for the treatment of ocular disorders. | |
| Ayyala et al. | Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes | |
| US8906427B2 (en) | Treatment for meibomian gland dysfunction or obstruction | |
| BRPI0608152A2 (en) | eye care formulations | |
| Yue et al. | Neuroprotective effect of curcumin against oxidative damage in BV-2 microglia and high intraocular pressure animal model | |
| JP2019534867A5 (en) | ||
| EA201490163A1 (en) | KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE | |
| JP7378781B2 (en) | Treatment of symptoms associated with neurodegenerative disorders through pharmacological transcutaneous activation of cranial nerves | |
| EA201490277A1 (en) | KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE | |
| EP2331095A4 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2015138628A8 (en) | Use of aav-expressed m013 protein as an anti-inflammatory therapeutic | |
| ECSP22086300A (en) | COMPOSITIONS INCLUDING NANOPARTICLES, METHOD OF PREPARATION AND USES THEREOF | |
| MX2020006309A (en) | Isoxazoline parasiticide formulations and methods for treating blepharitis. | |
| Deng et al. | Danhong enhances recovery from residual dizziness after successful repositioning treatment in patients with benign paroxysmal positional vertigo | |
| MX2022013665A (en) | Heterodimer compositions and methods for the treatment of ocular disorders. | |
| KR102256185B1 (en) | Methods for treating and preventing ocular diseases, disorders, and conditions with melanin and melanin analogs, precursors, and derivatives | |
| CL2020001426A1 (en) | Topical ophthalmic composition comprising dobesilic acid to treat diseases of the posterior segment of the eye. | |
| MX2023004538A (en) | Compounds and methods for the treatment of ocular disorders. | |
| MX2023004539A (en) | Compounds and methods for the treatment of ocular disorders. | |
| AU2022370385A1 (en) | Compounds and methods for the treatment of dermal and ocular disorders | |
| AU2020299145A8 (en) | Compositions and methods for treating eye diseases | |
| JP2022530471A (en) | Composition and Usage of Cannabinoids for Neuroprotection | |
| MX2021009384A (en) | Methods for treating symptoms and disorders associated with lysosomal storage diseases. | |
| MX2021016055A (en) | Isoxazoline parasiticide formulations and methods for treating blepharitis. |